Clinical trials: Epilepsy, Partial
Epilepsy
A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug
A pediatric drug study to determine the long-term safety and tolerability in children and adolescents (4-17 years in age) taking the drug (elsicarbazepine acetate)
- Trial name
- NCT03108729
- Testing
- Eslicarbazepine acetate
- Where
- United States
- Sponsor
- Sumitomo Pharma America, Inc.
Refractory Partial Onset Seizures
Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
This was an open-label extension study in adolescent and adult (between 12 and 80 years old) participants who had completed their participation in Study E2080-A001-301.
- Trial name
- NCT00448539
- Testing
- Rufinamide
- Where
- 27 sites in United States
- Volunteers
- 286 people
- Sponsor
- Eisai Inc.
Refractory Epilepsy, Focal Seizure
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers…
- Conditions
- Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures
- Trial name
- NCT04770337
- Testing
- STARSTIM device
- Where
- 32 sites in United States, Belgium and 2 more
- Volunteers
- 127 people
- Sponsor
- Neuroelectrics Corporation
Partial Epilepsies, Partial Onset Seizures
Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures
The purpose of the trial is to evaluate the safety of intravenous (iv) lacosamide delivered in a single dose followed by 6.5 days of oral lacosamide treatment in subjects with partial-onset seizures.
- Trial name
- NCT00655551
- Testing
- lacosamide
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Epilepsy, Monotherapy
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
Compare safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with primary safety variables including spontaneous reports of Adverse Events (AEs)…
- Trial name
- NCT01465997
- Testing
- Lacosamide, Carbamazepine-Controlled Release (CBZ-CR)
- Where
- 150 sites in United States, Australia and 27 more
- Volunteers
- 551 people
- Sponsor
- UCB BIOSCIENCES GmbH
Epilepsies, Partial, Epilepsy, Tonic-Clonic
Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study
Evaluate the initial safety and effectiveness of Microburst VNS stimulation in subjects with refractory epilepsy.
- Trial name
- Microburst (NCT03446664)
- Testing
- Microburst Stimulation
- Where
- 9 sites in United States, Belgium
- Volunteers
- 33 people
- Sponsor
- LivaNova
Epilepsies, Partial, Epilepsy Intractable
Contribution of Genetics, Non-invasive Methods and Neuropsychology in Focal Cryptogenic Epilepsies
Patients with cryptogenic focal epilepsy (unknown cause) represent about the 30% of the entire population of epilepsy patients. Among them, about 30% are drug-resistant.
- Trial name
- NCT05015868
- Testing
- Standard of care, Functional magnetic resonance imaging-Electroencephalogram combined analysis, High density- electroencephalogram or 7 Tesla magnetic resonance imaging
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- IRCCS Eugenio Medea
Focal Epilepsy
The Human Epilepsy Project
HEP is a five-year, prospective, observational study whose primary goal is to identify clinical characteristics and biomarkers predictive of disease outcome, progression, and treatment response in participants with newly treated…
- Trial name
- HEP (NCT02126774)
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 488 people
- Sponsor
- NYU Langone Health
Epilepsy, Seizures
A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy
The purpose of this study is to identify patient characteristics (such as baseline seizure frequency) that may predict effective doses of topiramate using just that one drug (monotherapy) as initial therapy for epilepsy.
- Conditions
- Epilepsy, Seizures, Epilepsies, Partial, Epilepsy, Generalized
- Trial name
- NCT00266604
- Testing
- Topiramate
- Volunteers
- 409 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Epilepsy
Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
The purpose of this study was to evaluate the safety and tolerability of perampanel (up to 12 mg/day) given as adjunctive treatment in subjects with refractory partial seizures and to evaluate the maintenance of effect of…
- Trial name
- NCT00735397
- Testing
- perampanel
- Where
- 239 sites in United States, Argentina and 37 more
- Volunteers
- 1,218 people
- Sponsor
- Eisai Inc.
Epilepsy
Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures
This open-label extension trial will assess the long-term use of Lacosamide monotherapy and safety of Lacosamide monotherapy and adjunctive therapy in subjects with partial-onset seizures who were previously enrolled in the…
- Trial name
- NCT00530855
- Testing
- Lacosamide
- Where
- 108 sites in United States, Australia and 7 more
- Volunteers
- 322 people
- Sponsor
- UCB Pharma